U.S. markets closed

Processa Pharmaceuticals, Inc. (PCSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4301-0.0213 (-4.72%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close0.4514
Bid0.4403 x 900
Ask0.4490 x 800
Day's Range0.4001 - 0.4725
52 Week Range0.3850 - 4.0100
Avg. Volume295,993
Market Cap10.524M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)-1.0000
Earnings DateMar 28, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PCSA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Processa Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/21/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

    The 300 mg dose group will provide more information on the drug exposure vs adverse event relationship which is critical to FDA approval given the FDA’s Project Optimus Oncology initiative.Patients treated with Next Generation Chemotherapy-Capecitabine have NOT had hand-foot syndrome or cardiotoxicity adverse events, typically seen in 50-70% of patients presently on FDA-approved capecitabine.In mid-April Processa expects guidance from FDA on our Phase 2B trial design and our Project Optimus appr

  • GlobeNewswire

    Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

    HANOVER, MD, March 07, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), the developer of the Next Generation Chemotherapy drugs that will provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that the Company’s President & CEO, Dr. David Young, will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 12:00 PM Eastern. The company is looking forward to

  • GlobeNewswire

    Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

    Our Next Generation Chemotherapies (NGCs) are cancer treatments where the metabolism and/or distribution of an FDA-approved drug has been altered to provide potentially safer and more effective chemotherapy to cancer patients.Based on preliminary clinical and pre-clinical studies, more cancer patients should benefit from our NGCs than their FDA-approved counterpart drugs.Our Regulatory Science approach, encompassing the principles of FDA’s Project Optimus and Oncology Guidance, should increase t